35 results about "Noise-induced hearing loss" patented technology

Devices and methods for digital sound leveling are disclosed. The subject devices and methods can be used to reduce the risk of noise induced hearing loss. According to an embodiment, an audio file can be parsed into frames that are filtered using an A-weighted digital filter and scaled to a desired power level. Accordingly, the dynamic range of an audio output at a particular volume level can be controlled.

An apparatus is disclosed for managing the joint contribution of noise exposure of the ear of a user of the apparatus from a loudspeaker of the apparatus as well as from ambient noise so that the risk of risk of noise induced hearing losses is reduced. By assessing the joint actual sound energy delivered to the ear and feeding said assessment to a model describing the accumulated risk of hearing loss due to said sound energy accumulated over a time period, an estimate of the current risk of hearing loss is obtained. When said risk estimate passes a predetermined threshold, one or more protective measures are taken.

A sound monitoring control for controlling the sound pressure level (SPL) delivered to the ears of a user of a hearing protection device. The control employs a measurement of the actual sound heard by the user, using a microphone to control the sound level and to help prevent noise induced hearing loss. A measurement, using a dosimeter microphone, of the actual sound pressure levels heard by the user can be used in audio processing schemes to ensure that the user is only exposed to safe levels.

Devices and methods for digital sound leveling are disclosed. The subject devices and methods can be used to reduce the risk of noise induced hearing loss. According to an embodiment, an audio file can be parsed into frames that are filtered using an A-weighted digital filter and scaled to a desired power level. Accordingly, the dynamic range of an audio output at a particular volume level can be controlled.

Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. Embodiments of the methods employ zonisamide as the sole active pharmaceutical agent or a combination of zonisamide and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI / NMDA antagonist agent. Other embodiments of the method involve the use of zonisamide alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss. Hearing disorders treatable with the invention include noise-induced hearing loss, drug-induced hearing loss, central auditory hearing disorder (CAPD), tinnitus and presbyacusis.

A method of avoiding harmful noise levels, the method comprising implementing a cognitive suite of workplace hygiene and injury predictors (WHIP) that has learned to identify noise sources and indicators of harmful noise levels, detecting an indicator, and implementing a corrective action by at least one of altering the operation of a noise source, modifying a time of a scheduled task, or changing prescribed personal protective equipment.

The invention discloses a drug or health care product for preventing and treating hearing loss and relates to the technical field of biological medicine and health care products. Aiming at the defects that there are not many drugs for treating hearing loss in the market currently, the treatment effect is poor, and health care products with the corresponding function are unavailable, the effective and well-targeted drug for preventing and treating hearing loss and the corresponding health care product, especially the drug which has a special effect on sensorineural hearing loss including age-related hearing loss, noise induced hearing loss and sudden hearing loss and the corresponding health care product are provided. The drug or health care product contains the active constituent nicotinamide mononucleotide. The drug or health care product has the advantages of being capable of becoming effective quickly, high in treatment effect, stable in efficacy, free of toxic or side effect on human body and the like.

Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing.

The invention relates to a noise stimulation box, which has a main function of providing a noise giving environment for experimental animals during noise stimulation. The noise stimulation box is implemented by a lightweight sound insulation component and a double-layer composite sound insulation structure in order to improve the sound insulation performance and meet the special requirements of the noise simulation box on ventilation, fireproofness, moisture proofness, corrosion resistance and the like. The noise stimulation box disclosed by the invention furthest ensures the strength stability and the minimum attenuation after a noise signal of a signal generator is output, furthest meets the requirements on normalization of noise stimulation models and provides an effective environment foundation for establishment of the noise-induced deaf animal models. The noise stimulation box relates to the field of scientific research of the experimental animals, sound wave barrier sound-absorbing materials, physical ventilation and the like and is suitable for establishment of various noise-induced hearing loss animal models and sound stimulation models as well as behavior surveillance of the experimental animals under the noise exposure.

Ototoxic side-effects have either limited the application of an important group of antibiotics, aminoglycoside antibiotics, or have added further burden to those who have to resort to platinum-containing antineoplastic agents to treat life-threatening tumors. The present invention discloses pharmaceutical compositions that prevent or treat the ototoxic side-effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents. The otoprotective compositions disclosed herein can also be used to treat noise induced hearing loss.

An animal noise stimulation system comprises a computer monitor, a video signal collector, an audio power amplifier, a lighting system, an audio sensor, a camera and an air renewal system. The computer monitor displays audio waveforms, audio sound intensities and videos. The video signal collector which includes a signal source software and an audio signal collector is used for collecting signals from the audio sensor and the camera and sending feedback to the computer monitor for audio and video display. The lighting system includes two visible light sources. The camera can monitor animals' behavior reactions to noises. The air renewal system can facilitate the exchange and renewal of air inside and outside a noise case. The animal noise stimulation system uses the power amplifier and the noise case to amplify the noises for simulating different noise environments to complete the establishment of the hearing-impaired animal models and uses computer for data transmitting and audio acquisition and analysis to detect the impair of noise stimulation to animal auditory physiological system for quantifying and evaluating, thereby providing experimental data for the prevention and treatment of noise-induced hearing loss.

The invention discloses a nutritional agent with noise reduced hearing loss resistance. The nutritional agent is prepared from the following raw materials in parts by weight: 600-1000 parts of N-acetyl-L-cysteine, 1-4 parts of vitamin A, 1-5 parts of vitamin B1, 1-5 parts of vitamin B2, 1-10 parts of vitamin B6, 0.01-0.05 part of vitamin B12, 60-1000 parts of vitamin C, 15-300 parts of vitamin E which is based on alpha-totaxin, 50-400 parts of magnesium and 79-3175 parts of food acceptable accessories. Experiment data displays that the nutritional agent has remarkable effect of preventing and controlling the noise induced hearing loss. The nutritional agent can be used for enhancing the anti-oxidation ability of the organism and lightening the exitotoxicity damage, has the characteristics of being remarkable in curative effect, low in potential toxicity and low in cost, and is suitable for the noise reduced hearing loss protection and daily nutrient supplementation of people who live and work in the environment with continuous exposed high-intensity noise.

The invention provides an application of sodium butyrate for preventing noise-induced hearing loss, and belongs to the technical field of biological medicine. According to the application of sodium butyrate for preventing noise-induced hearing loss, in the noise-induced hearing loss experiment of mice models, sodium butyrate can reduce the auditory brainstem response threshold shift after noise exposure, increase the survival rate of cochlear hair cells after noise exposure, has excellent noise-induced hearing loss preventing effect on noises at multiple frequencies, especially has excellent preventative effect on noise-induced hearing loss, explosive hearing loss and other diseases, can be used for preparing drugs and / or healthcare products for preventing noise-induced hearing loss, has good research and application prospects, and can fill in the gap of drugs for preventing noise-induced hearing loss at present.

A method of avoiding harmful noise levels, the method comprising implementing a cognitive suite of workplace hygiene and injury predictors (WHIP) that has learned to identify noise sources and indicators of harmful noise levels, detecting an indicator, and implementing a corrective action by at least one of altering the operation of a noise source, modifying a time of a scheduled task, or changing prescribed personal protective equipment.

Loud sounds with fast rise times, like gunfire and explosions, can cause noise-induced hearing loss (NIHL). Unfortunately, current models do not adequately explain how impulsive sounds cause NIHL, which makes it difficult to predict and prevent NIHL on battlefields and other hostile or rugged environments. Fortunately, the impulsive sounds experienced by soldiers and others working in rugged environments can be recorded using a compact, portable system that acquires, digitizes, and stores high-bandwidth audio data. An example of this system can be mounted on a helmet or other article and used to record hours of audio data at a bandwidth of 20 kHz or higher, which is broad enough to capture sounds with rise times less than 50 ms. An analog-to-digital converter (ADC) digitizes these broadband audio signals at rate of 40 kHz or higher to preserve the impulse information. A processor transfers the digitized samples from a buffer to a memory card for later retrieval using an interrupt-driven processing technique.

A method for treating noise-induced hearing loss (NIHL) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and / or resveratrol.

The invention relates to a method and kit for detecting an SNP (Single Nucleotide Polymorphism) site rs10081191 of a susceptible gene region 7q36.3 related to a disease risk of NIHL (Noise Induced Hearing Loss), and application. The method is Sequenom typing. The invention further relates to the kit for detecting the susceptible site and application of the kit. In addition, the SNP site rs10081191of the region 7q36.3 is associated with the disease risk of the NIHL, and the invention discloses the SNP and application thereof. The SNP is located in a human genome region 7q36.3, the 7q36.3 is determined to be a new susceptible gene region of the NIHL, and the SNP can be effectively used for screening susceptible groups of the noise induced hearing loss diseases and determining susceptible individuals of the noise induced hearing loss diseases.

The invention discloses a nutritional agent with noise reduced hearing loss resistance. The nutritional agent is prepared from the following raw materials in parts by weight: 600-1000 parts of N-acetyl-L-cysteine, 1-4 parts of vitamin A, 1-5 parts of vitamin B1, 1-5 parts of vitamin B2, 1-10 parts of vitamin B6, 0.01-0.05 part of vitamin B12, 60-1000 parts of vitamin C, 15-300 parts of vitamin E which is based on alpha-totaxin, 50-400 parts of magnesium and 79-3175 parts of food acceptable accessories. Experiment data displays that the nutritional agent has remarkable effect of preventing and controlling the noise induced hearing loss. The nutritional agent can be used for enhancing the anti-oxidation ability of the organism and lightening the exitotoxicity damage, has the characteristics of being remarkable in curative effect, low in potential toxicity and low in cost, and is suitable for the noise reduced hearing loss protection and daily nutrient supplementation of people who live and work in the environment with continuous exposed high-intensity noise.

The present invention provides methods of preventing, treating, and / or reducing noise induced hearing loss and / or noise-induced inner ear trauma. The methods include the administration of glatiramer acetate or a derivative thereof and, optionally, at least one anti-oxidant.

A method for treating noise-induced hearing loss (NIHL) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and / or resveratrol.

The present invention is related to a pharmaceutical composition and health food for preventing or treating hearing loss, wherein the pharmaceutical composition and health food contain carbenoxolone or its pharmaceutically acceptable salts as an effective component. More particularly, a composition including carbenoxolone or its pharmaceutically acceptable salts as an effective component is provided as a pharmaceutical composition for preventing or treating ototoxic hearing loss due to the carbenoxolone or its pharmaceutically acceptable salts prevent damages on auditory cells from ototoxic drugs such as cisplatin anticancer drugs, and the composition may be used as a drug for treating noise-induced hearing loss and age-related hearing loss, as well as ototoxic hearing loss.

The invention relates to application of melbine in preparing an NIHL (Noise Induced Hearing Loss) prevention product. A pharmacological experiment of a prevention function of the melbine on noise exposure mouse hearing loss shows that the melbine is capable of remarkably preventing and therapeutically protecting hearing loss caused by noise exposure and shows that the melbine has a function of preventing the NIHL. According to the application disclosed by the invention, experimental research on the melbine verifies new application of the melbine in preventing the NIHL.

The present invention provides methods of preventing, treating, and / or reducing noise induced hearing loss and / or noise-induced inner ear trauma. The methods include the administration of glatiramer acetate or a derivative thereof and, optionally, at least one anti-oxidant.

The invention discloses an application of Riviciclib hydrochloride (p276-00) in preparation of a medicine for preventing and treating noise induced hearing loss, relates to the field of medicines, and aims to solve the problem that existing medicines for preventing and treating noise induced hearing loss are rare. According to the invention, with the application of the noise induced hearing loss animal model experiment method, the hearing, the internal hair cell function and the like of the mouse after the noise exposure are detected, it is found that the Riviciclib hydrochloride (p276-00) has the good protection effect on the number and the function of the internal hair cell synapses during the noise exposure, the prevention and treatment effect of the Riviciclib hydrochloride (p276-00) on the noise induced hearing loss is directly verified, and the Riviciclib hydrochloride (p276-00) can be used for preparing the medicines for preventing and treating the noise induced hearing loss and has good research and application prospects.

The invention discloses the application of an ionotropic glutamate receptor in the preparation of medicine for treating noise-induced hearing loss. Experiments showed that the protein expression levels of GluR1, GluR2, NR2A, NR2B, and NR1 receptors decreased in different degrees in A1 and MGB regions, and their mRNA expression levels also decreased in different degrees. Among them, the down-regulation of NR2A receptor protein expression and mRNA expression level is particularly obvious, and it should be an ideal new drug target for the treatment of noise-induced hearing loss.

The present invention relates to a pharmaceutical composition for preventing or treating hearing loss, containing cilostazol and a ginkgo leaf extract as active ingredients. The pharmaceutical composition can effectively prevent or treat noise-induced hearing loss or ototoxic hearing loss by inhibiting the apoptosis of hair cells due to the generation of reactive oxygen species (ROS).

The invention provides an application of sodium butyrate for preventing noise-induced hearing loss, and belongs to the technical field of biological medicine. According to the application of sodium butyrate for preventing noise-induced hearing loss, in the noise-induced hearing loss experiment of mice models, sodium butyrate can reduce the auditory brainstem response threshold shift after noise exposure, increase the survival rate of cochlear hair cells after noise exposure, has excellent noise-induced hearing loss preventing effect on noises at multiple frequencies, especially has excellent preventative effect on noise-induced hearing loss, explosive hearing loss and other diseases, can be used for preparing drugs and / or healthcare products for preventing noise-induced hearing loss, has good research and application prospects, and can fill in the gap of drugs for preventing noise-induced hearing loss at present.

The invention relates to a noise stimulation box, which has a main function of providing a noise giving environment for experimental animals during noise stimulation. The noise stimulation box is implemented by a lightweight sound insulation component and a double-layer composite sound insulation structure in order to improve the sound insulation performance and meet the special requirements of the noise simulation box on ventilation, fireproofness, moisture proofness, corrosion resistance and the like. The noise stimulation box disclosed by the invention furthest ensures the strength stability and the minimum attenuation after a noise signal of a signal generator is output, furthest meets the requirements on normalization of noise stimulation models and provides an effective environment foundation for establishment of the noise-induced deaf animal models. The noise stimulation box relates to the field of scientific research of the experimental animals, sound wave barrier sound-absorbing materials, physical ventilation and the like and is suitable for establishment of various noise-induced hearing loss animal models and sound stimulation models as well as behavior surveillance of the experimental animals under the noise exposure.